95 related articles for article (PubMed ID: 21641337)
1. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands.
de Medina P; Paillasse MR; Ségala G; Khallouki F; Brillouet S; Dalenc F; Courbon F; Record M; Poirot M; Silvente-Poirot S
Chem Phys Lipids; 2011 Sep; 164(6):432-7. PubMed ID: 21641337
[TBL] [Abstract][Full Text] [Related]
2. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.
Payré B; de Medina P; Boubekeur N; Mhamdi L; Bertrand-Michel J; Tercé F; Fourquaux I; Goudounèche D; Record M; Poirot M; Silvente-Poirot S
Mol Cancer Ther; 2008 Dec; 7(12):3707-18. PubMed ID: 19074846
[TBL] [Abstract][Full Text] [Related]
3. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism.
de Medina P; Payré B; Boubekeur N; Bertrand-Michel J; Tercé F; Silvente-Poirot S; Poirot M
Cell Death Differ; 2009 Oct; 16(10):1372-84. PubMed ID: 19521424
[TBL] [Abstract][Full Text] [Related]
4. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands.
de Medina P; Paillasse MR; Segala G; Poirot M; Silvente-Poirot S
Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13520-5. PubMed ID: 20615952
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of the microsomal tamoxifen binding site.
Kedjouar B; de Médina P; Oulad-Abdelghani M; Payré B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
J Biol Chem; 2004 Aug; 279(32):34048-61. PubMed ID: 15175332
[TBL] [Abstract][Full Text] [Related]
6. 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells.
Segala G; de Medina P; Iuliano L; Zerbinati C; Paillasse MR; Noguer E; Dalenc F; Payré B; Jordan VC; Record M; Silvente-Poirot S; Poirot M
Biochem Pharmacol; 2013 Jul; 86(1):175-89. PubMed ID: 23500540
[TBL] [Abstract][Full Text] [Related]
7. From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite.
Silvente-Poirot S; de Medina P; Record M; Poirot M
Biochimie; 2016 Nov; 130():109-114. PubMed ID: 27262406
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol epoxide hydrolase and cancer.
Silvente-Poirot S; Poirot M
Curr Opin Pharmacol; 2012 Dec; 12(6):696-703. PubMed ID: 22917620
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation.
de Medina P; Silvente-Poirot S; Poirot M
Autophagy; 2009 Oct; 5(7):1066-7. PubMed ID: 19738414
[TBL] [Abstract][Full Text] [Related]
10. Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death.
Leignadier J; Dalenc F; Poirot M; Silvente-Poirot S
Biochem Pharmacol; 2017 Nov; 144():18-28. PubMed ID: 28642035
[TBL] [Abstract][Full Text] [Related]
11. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor.
Kedjouar B; Daunes S; Vilner BJ; Bowen WD; Klaebe A; Faye JC; Poirot M
Biochem Pharmacol; 1999 Dec; 58(12):1927-39. PubMed ID: 10591147
[TBL] [Abstract][Full Text] [Related]
12. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
Watts CK; Sutherland RL
Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
[TBL] [Abstract][Full Text] [Related]
13. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism.
Sola B; Poirot M; de Medina P; Bustany S; Marsaud V; Silvente-Poirot S; Renoir JM
Oncotarget; 2013 Jun; 4(6):911-22. PubMed ID: 23978789
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.
de Medina P; Payré BL; Bernad J; Bosser I; Pipy B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
J Pharmacol Exp Ther; 2004 Mar; 308(3):1165-73. PubMed ID: 14617686
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS).
Poirot M; De Medina P; Delarue F; Perie JJ; Klaebe A; Faye JC
Bioorg Med Chem; 2000 Aug; 8(8):2007-16. PubMed ID: 11003145
[TBL] [Abstract][Full Text] [Related]
17. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
Suárez Y; Fernández C; Gómez-Coronado D; Ferruelo AJ; Dávalos A; Martínez-Botas J; Lasunción MA
Cardiovasc Res; 2004 Nov; 64(2):346-55. PubMed ID: 15485695
[TBL] [Abstract][Full Text] [Related]
18. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.
de Médina P; Favre G; Poirot M
Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):491-508. PubMed ID: 15579015
[TBL] [Abstract][Full Text] [Related]
19. Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.
Watts CK; Sutherland RL
Biochem J; 1986 Jun; 236(3):903-11. PubMed ID: 3790095
[TBL] [Abstract][Full Text] [Related]
20. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
